Apellis Pharmaceuticals Inc (APLS)
27.73
+0.24
(+0.87%)
USD |
NASDAQ |
Nov 21, 16:00
27.73
0.00 (0.00%)
After-Hours: 20:00
Apellis Pharmaceuticals Enterprise Value: 3.475B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
November 20, 2024 | 3.475B |
November 19, 2024 | 3.662B |
November 18, 2024 | 3.312B |
November 15, 2024 | 3.323B |
November 14, 2024 | 3.546B |
November 13, 2024 | 3.569B |
November 12, 2024 | 3.695B |
November 11, 2024 | 3.735B |
November 08, 2024 | 3.785B |
November 07, 2024 | 3.630B |
November 06, 2024 | 3.642B |
November 05, 2024 | 3.548B |
November 04, 2024 | 3.608B |
November 01, 2024 | 3.536B |
October 31, 2024 | 3.446B |
October 30, 2024 | 3.502B |
October 29, 2024 | 3.465B |
October 28, 2024 | 3.393B |
October 25, 2024 | 3.312B |
October 24, 2024 | 3.422B |
October 23, 2024 | 3.349B |
October 22, 2024 | 3.424B |
October 21, 2024 | 3.337B |
October 18, 2024 | 3.473B |
October 17, 2024 | 3.464B |
Date | Value |
---|---|
October 16, 2024 | 3.467B |
October 15, 2024 | 3.467B |
October 14, 2024 | 3.398B |
October 11, 2024 | 3.368B |
October 10, 2024 | 3.311B |
October 09, 2024 | 3.339B |
October 08, 2024 | 3.400B |
October 07, 2024 | 3.406B |
October 04, 2024 | 3.413B |
October 03, 2024 | 3.481B |
October 02, 2024 | 3.532B |
October 01, 2024 | 3.442B |
September 30, 2024 | 3.576B |
September 27, 2024 | 3.686B |
September 26, 2024 | 3.732B |
September 25, 2024 | 3.822B |
September 24, 2024 | 3.841B |
September 23, 2024 | 4.081B |
September 20, 2024 | 4.056B |
September 19, 2024 | 4.570B |
September 18, 2024 | 4.436B |
September 17, 2024 | 4.423B |
September 16, 2024 | 4.518B |
September 13, 2024 | 4.678B |
September 12, 2024 | 4.576B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.140B
Minimum
Mar 17 2020
10.19B
Maximum
Jun 13 2023
4.423B
Average
4.224B
Median
Enterprise Value Benchmarks
Biomarin Pharmaceutical Inc | 11.59B |
Ionis Pharmaceuticals Inc | 4.385B |
EyePoint Pharmaceuticals Inc | 357.39M |
Cassava Sciences Inc | 1.104B |
Macrogenics Inc | 5.501M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -57.44M |
Revenue (Quarterly) | 196.83M |
Total Expenses (Quarterly) | 244.11M |
EPS Diluted (Quarterly) | -0.46 |
Gross Profit Margin (Quarterly) | 82.95% |
Profit Margin (Quarterly) | -29.19% |
Earnings Yield | -7.32% |
Normalized Earnings Yield | -7.276 |